Navigation Links
Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
Date:11/20/2012

p>

About Ohr Pharmaceutical Inc.

Ohr Pharmaceutical Inc. (OTCBB: OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The company is focused on two lead compounds currently being investigated in clinical phase II trials: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the company can be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: 
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent A
'/>"/>

SOURCE Ohr Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isis Pharmaceuticals To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
3. Global Pharmaceuticals & Medicine Manufacturing
4. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
5. Active Pharmaceutical Ingredients (API) Global Market to 2017 - Growth in Developing Markets to Come From Cost Efficient Manufacturing and Rising Domestic Demand
6. Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
7. Clinical Trial Strategies to Ensure Pharmaceutical Success in a Global Marketplace
8. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
9. Building on a Legacy: Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., Named Ernst & Young U.S. 2012 Family Business Award of Excellence winner
10. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
11. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... July 19, 2011 Spanish drug companies face a ... the United States.  From regulatory (FDA) and GMP compliance, ... there are many areas that must be coordinated.  Those ... company KIM and U.S. company VPCI have entered into ...
... July 19, 2011 Reportlinker.com announces that ... in its catalogue: The ... Discovery http://www.reportlinker.com/p0574968/The-Changing-Role-of-Natural-Products-in-Drug-Discovery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ... This report reveals how natural products have ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2The Changing Role of Natural Products in Drug Discovery 2The Changing Role of Natural Products in Drug Discovery 3The Changing Role of Natural Products in Drug Discovery 4
(Date:4/24/2014)... WINSTON-SALEM, N.C. April 24, 2014 ,Take me ... of apple slices and kale chips. The more likely ... of Crackerjacks. , Unfortunately for children who play ... may be contributing to weight problems, according to researchers ... in the current online edition of Childhood Obesity ...
(Date:4/24/2014)... Richard Plemper, a professor in the new Institute ... received a five-year, $2.83 million federal grant to ... infection. , The grant from the Eunice Kennedy ... Development of the National Institutes of Health will ... anti-RSV drug and at least one distinct alternative ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... the first in the world to discover a gene ... jaw. , Ameloblastoma is an odontogenic tumour with a ... often found in the posterior of the lower jaw. ... deficiencies in the jaws as well as loss of ... need for surgery and the recurrence of ameloblastoma, but ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
... twins found that exposure to trichloroethylene (TCE) -- a ... -- is significantly associated with increased risk of Parkinson,s ... also linked to perchloroethylene (PERC) and carbon tetrachloride (CCI4) ... Annals of Neurology , a journal published by Wiley-Blackwell ...
... of the brain responsible for pain processing and ... following a medication holiday, say researchers from Georgetown ... indicate brain functioning is more streamlined after an ... is devoted to processing bothersome fibromyalgia perceptions such ...
... Diego School of Medicine and the UC San Diego ... approach enabling the destruction of the most highly proliferative ... issue of the journal Nature Medicine , points ... cells without causing some of the negative effects of ...
... , SUNDAY, Nov. 13 (HealthDay News) -- Unborn ... the heart transplant list before birth get new hearts more ... study. The findings are to be presented Tuesday ... After reviewing cases of fetal heart patients, including 46 ...
... , FRIDAY, Nov. 11 (HealthDay News) -- All ... be screened for high cholesterol, according to new guidelines endorsed ... are a major shift from current guidelines that suggest such ... history of heart disease or high blood cholesterol, which is ...
... will soon reduce reimbursements to some dialysis facilities, ... to drive further to get care at other ... People initiative provides 10-year national objectives for improving ... presents new kidney-related objectives., Two studies presented ...
Cached Medicine News:Health News:Parkinson's disease risk greater in those exposed to trichloroethylene 2Health News:Improved memory efficiency seen after aerobic exercise in fibromyalgia patients 2Health News:New way to target - and kill - proliferating tumors 2Health News:Babies Put on Transplant List Before Birth Get Hearts Faster 2Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 2Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 3Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 4Health News:Kidney disease care -- what's in store for the future? 2
Mayfield Disposable Adult (plastic) Skull Pins are designed for rigid skeletal fixation....
... borescopes are rigid endoscopes for general applications and ... The diameters of borescopes, i.e. rigid endoscopes, range ... directions from 0 up to a 120 retrospection, ... and wide angle view. Endoscopes with working lengths ...
Long system ventriculoscope for stereotactic frames....
... a new biological material produced ... collagen implant, lyoplant can absorb ... replacing implant material with the ... structure minimizes suture channels, resulting ...
Medicine Products: